FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely immunology, and can be used in assessing the level of antiplague immunity. That is ensured by applying a complex of water-soluble antigens of plague microbe with protein concentration of 4.5 mg/ml in antigen-specific cell tests in vitro using flow cytometry technology as a lymphocyte activator.
EFFECT: use of a complex of water-soluble antigens of plague microbe in protein concentration of 4_5 mg/ml has the greatest stimulating potential in vitro in relation to lymphocytes expressing the CD25 receptor.
1 cl, 3 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING IMMUNOGENICITY OF LIVE PLAGUE VACCINE USING IN VITRO ANTIGEN SPECIFIC CELLULAR TESTS | 2018 |
|
RU2680697C1 |
| METHOD FOR ASSESSING ACTUAL VACCINATION OF PEOPLE AGAINST BRUCELLOSIS IN THE EARLY STAGES AFTER VACCINATION | 2019 |
|
RU2714136C1 |
| METHOD OF OBTAINING A BRUCELLAROTIC ANTIGEN FOR CELL TESTS IN VITRO | 2019 |
|
RU2708561C1 |
| METHOD FOR ASSESSING PROTECTIVE IMMUNITY AGAINST CAUSATIVE AGENT OF BRUCELLOSIS | 2022 |
|
RU2806161C1 |
| METHOD FOR IMMUNOLOGICAL DIAGNOSIS OF BRUCELLOSIS | 2022 |
|
RU2785906C1 |
| METHOD FOR SELECTION OF SUBSTANCES FOR DIRECTED IMMUNE RESPONSE MODULATION AFTER VACCINATION AGAINST PLAGUE | 2016 |
|
RU2621303C1 |
| METHOD FOR INCREASING IMMUNOGENICITY OF VACCINE STRAIN OF PLAGUE MICROBE | 2019 |
|
RU2727258C1 |
| METHOD FOR DETERMINING THE SPECIFIC CELLULAR IMMUNE RESPONSE TO CORONAVIRUS ANTIGENS (SARS-CoV-2) | 2021 |
|
RU2780369C1 |
| METHOD FOR ASSESSING POSTVACCINAL IMMUNITY AGAINST BRUCELLOSIS | 2019 |
|
RU2740009C1 |
| METHOD FOR PROGNOSTICATION OF CLINICAL EFFECTIVENESS OF ANTIBACTERIAL, VACCINE PREPARATIONS, AGENTS FOR PASSIVE ANTITOXIC IMMUNOTHERAPY ON MODEL OF INFECTIOUS-TOXIC PLAGUE FORM IN MICE | 2005 |
|
RU2303821C2 |
